United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

27 Jul 2016
Change (% chg)

¥-28 (-1.13%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo Co Ltd and Asubio Pharmaceuticals Inc merge
Wednesday, 1 Apr 2015 08:00am EDT 

Daiichi Sankyo Co Ltd:Says it will merge with its US-based sister company, Asubio Pharmaceuticals Inc.Says Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as wholly owned subsidiary of Daiichi Sankyo Co Ltd with focus on discovery research.  Full Article

Sun Pharmaceutical Industries acquires stake in Ranbaxy Laboratories from Daiichi Sankyo
Wednesday, 25 Mar 2015 02:30am EDT 

Daiichi Sankyo Co Ltd:Sun Pharmaceutical Industries Ltd completed acquisition of stake in Ranbaxy Laboratories, which was a 63.4 pct-owned subsidiary of Daiichi Sankyo, through stock swap, on March 24.Plan disclosed on April 7, 2014.  Full Article

Daiichi Sankyo subsidiary signs co-commercialization agreement with AstraZeneca
Thursday, 19 Mar 2015 03:00am EDT 

Daiichi Sankyo Co Ltd:An U.S-based subsidiary signed a co-commercialization agreement of MOVANTIK (generic name naloxegol) in U.S with a London-based company named AstraZeneca.MOVANTIK is a narcotic analgesic for treatment of induced constipation.  Full Article

Daiichi Sankyo announces civil settlement of U.S-based subsidiary
Monday, 12 Jan 2015 06:30pm EST 

Daiichi Sankyo Co Ltd:U.S-based subsidiary Daiichi Sankyo, Inc. announced that it has reached a civil settlement with the U.S. Government, as well as participating states to conclude a Federal investigation related to certain types of speaker programs related to Azor, Benicar, Benicar HCT, Welchol and Tribenzor.Under the agreement, the U.S-based subsidiary has agreed to pay approximately $39 million, plus fees and costs, and has entered into a Corporate Integrity Agreement with the Office of Inspector General for the U.S. Department of Health and Human Services.  Full Article

Daiichi Sankyo subsidiary gets FDA approval
Thursday, 8 Jan 2015 07:15pm EST 

Daiichi Sankyo Co Ltd:Says U.S.-based subsidiary received approval for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSATM (edoxaban) Tablets from the U.S. Food and Drug Administration (FDA), in U.S. on Jan. 8.Approval for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF), as well as for the treatment of venous thromboembolism.  Full Article

UCB SA announces partnership with Daiichi Sankyo in Japan
Friday, 28 Nov 2014 01:02am EST 

UCB SA:Announces partnership with Daiichi Sankyo for co-commercialization of Lacosamide in Japan.Says it will manufacture and supply product for commercialization, Daiichi Sankyo will manage distribution and book sales.Says it will receive from Daiichi Sankyo up to total of about 180 million euros of upfront and milestones payments during coming years.Payment is based on agreement and subject to achievement of certain milestones in future.Agreement does not change UCB's financial outlook for 2014.Impact from agreement on Daiichi Sankyo's business results of current fiscal year will be announced at later date.  Full Article

Daiichi Sankyo and Ambit Biosciences announce results of tender offer
Tuesday, 11 Nov 2014 01:00am EST 

Daiichi Sankyo Co Ltd:Announced the results of Daiichi Sankyo's tender offer to purchase all of the outstanding shares of Ambit Biosciences' common stock for $15.00 per share.Also plus one non-transferable contingent value right per share, which will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones relating to quizartinib.Says the tender offer is being effected by Daiichi Sankyo's subsidiary, Charge Acquisition Corp.A total of 15,674,238 shares of Ambit Biosciences common stock had been validly tendered and not withdrawn, representing approximately 85 pct of Ambit Biosciences’ outstanding shares.And all shares that were validly tendered and not withdrawn during the initial offering period have been accepted for payment.The condition to the tender offer that a majority of Ambit Biosciences' outstanding shares be validly tendered has been satisfied.Says Daiichi Sankyo's acquisition of Ambit Biosciences is expected to be completed later through a merger under Section of the General Corporation Law of the State of Delaware.Says as a result of the merger, each share of common stock of Ambit Biosciences not tendered in the tender offer will be converted into the right to receive $15.00 per share in cash, plus one non-transferable contingent value right per share.Says this is the same price per share paid in the tender offer.  Full Article

Daiichi Sankyo Co Ltd updates takeover bid offering to Ambit Biosciences
Monday, 13 Oct 2014 07:00pm EDT 

Daiichi Sankyo Co Ltd:Says began takeover bid offering to Ambit Biosciences through U.S-based subsidiary Charge Acquisition Corp. at price of $15 per share on Oct. 10 (eastern time of U.S).Says the deadline of takeover bid is planned on Nov. 10 (eastern time of U.S).Plan disclosed on Sep. 29.  Full Article

Perosphere and Daiichi Sankyo Co Ltd enter into clinical trial collaboration agreement for Phase 3 studies of PER977
Monday, 6 Oct 2014 11:50am EDT 

Perosphere and Daiichi Sankyo Co Ltd:Enter into Clinical Trial Collaboration Agreement for Phase 3 Studies of PER977 to Investigate Reversal of the Anticoagulant Activity of the Investigational Factor Xa-Inhibitor Edoxaban.Perosphere Inc. entered into third clinical trial collaboration agreement with Daiichi Sankyo, Inc. to study PER977, Perosphere's investigational anticoagulant reversal agent, in phase 3 registration studies with edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.  Full Article

Daiichi Sankyo Co Ltd to fully acquire Ambit Biosciences
Sunday, 28 Sep 2014 07:00pm EDT 

Daiichi Sankyo Co Ltd:To fully acquire Ambit Biosciences through a newly founded subsidiary at $315 million , or up to $410 million including additional consideration.  Full Article

BRIEF-Daiichi Sankyo plans 5th&6th series unsecured corporate bonds worth total 100 bln yen

* Says it plans to issue 5th series unsecured corporate bonds worth 75 billion yen, with coupon rate of 0.810 percent and maturity date on July 25, 2036